Olema Pharmaceuticals Azioni (NASDAQ: OLMA)

Ultime notizie per Olema Pharmaceuticals (NASDAQ:OLMA) Azioni

OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

MODV

OLMA

Le azioni sanitarie più promettenti da considerare per il quarto trimestre, con valutazioni attuali e proiezioni di crescita.

Le 3 azioni sanitarie da comprare ora: le migliori opportunità

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals inc

Throughout the last three months, 6 analysts have evaluated XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $24.83, a high estimate of $31.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 49.4% from the previous average price target of $16.62.
<img src="https://www.benzinga.com/files/images/story/2025/1747915299_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of XPeng's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eugene Hsiao</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Nick Lai</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ming Hsun Lee</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$18.60</td>
</tr>
<tr>
<td>Jeff Chung</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$13.70</td>
</tr>
<tr>
<td>Paul Gong</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$8.80</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to XPeng. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of XPeng compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for XPeng's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of XPeng's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XPEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on XPeng analyst ratings.</a>
<h2>Get to Know XPeng Better</h2>
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
<h3>Unraveling the Financial Story of XPeng</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: XPeng displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 23.41%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: XPeng's net margin excels beyond industry benchmarks, reaching -8.26%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): XPeng's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): XPeng's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.67% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: XPeng's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.51.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

XPEV

6 Analysts Have This To Say About XPeng

<a href="https://www.foxbusiness.com/video/5640669329001" title="https://www.foxbusiness.com/video/5640669329001">https://www.foxbusiness.com/video/5640669329001</a>

Macro Economic Events

Econ #s

Economics

Live On Fox Business Fed's Waller Says : Markets Are Watching Fiscal Policy And Have Concerns; Markets Are Looking For More Fiscal Discpline;  Fed Won't Buy Bonds In Primary Auctions; Hard Data Shows Economy Doing Quite Well, Scant Sign Of Tariff Impact So Far; If Tariffs Are Closer To 10% Then Economy In Good Shape For 2H

In the preceding three months, 6 analysts have released ratings for Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $34.83, a high estimate of $110.00, and a low estimate of $14.00. Experiencing a 3.25% decline, the current average is now lower than the previous average price target of $36.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1747915288_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vir Biotechnology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vir Biotechnology. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vir Biotechnology compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Vir Biotechnology's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vir Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VIR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vir Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Vir Biotechnology's Background</h2>
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
<h3>Breaking Down Vir Biotechnology's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Vir Biotechnology's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -96.5%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vir Biotechnology's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6742.75%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vir Biotechnology's ROE excels beyond industry benchmarks, reaching -11.03%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.94%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Vir Biotechnology's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Analysts' ratings for Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $235.75, along with a high estimate of $250.00 and a low estimate of $226.00. Highlighting a 0.11% decrease, the current average has fallen from the previous average price target of $236.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1747915270_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Guidewire Software by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$226.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$231.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Guidewire Software. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Guidewire Software compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Guidewire Software's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Guidewire Software's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GWRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Guidewire Software analyst ratings.</a>
<h2>All You Need to Know About Guidewire Software</h2>
Guidewire Software provides software solutions for property and casualty insurers. Flagship product InsuranceSuite is an on-premises system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a cloud-based offering, as well as a variety of other add-on applications.
<h3>Understanding the Numbers: Guidewire Software's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Guidewire Software showcased positive performance, achieving a revenue growth rate of 20.17% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Guidewire Software's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -12.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Guidewire Software's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.94%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Guidewire Software's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.45%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Guidewire Software's debt-to-equity ratio stands notably higher than the industry average, reaching 0.7. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

The Analyst Verdict: Guidewire Software In The Eyes Of 4 Experts

Throughout the last three months, 5 analysts have evaluated Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cooper Companies and provided 12-month price targets. The average target is $109.4, accompanied by a high estimate of $115.00 and a low estimate of $105.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.81%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747915249_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Cooper Companies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$107.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cooper Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cooper Companies compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cooper Companies's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cooper Companies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cooper Companies analyst ratings.</a>
<h2>Delving into Cooper Companies's Background</h2>
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
<h3>Financial Milestones: Cooper Companies's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, Cooper Companies showcased positive performance, achieving a revenue growth rate of 3.55% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cooper Companies's net margin is impressive, surpassing industry averages. With a net margin of 10.81%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cooper Companies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.29%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.85%, the company showcases effective utilization of assets.
Debt Management: Cooper Companies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Cooper Companies Stands With Analysts

Across the recent three months, 7 analysts have shared their insights on Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Integer Holdings, presenting an average target of $144.29, a high estimate of $150.00, and a low estimate of $140.00. Experiencing a 2.18% decline, the current average is now lower than the previous average price target of $147.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747915236_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Integer Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$145.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Integer Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Integer Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Integer Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Integer Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ITGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Integer Holdings analyst ratings.</a>
<h2>Get to Know Integer Holdings Better</h2>
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio &amp; Vascular, Cardiac Rhythm Management &amp; Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
<h3>Unraveling the Financial Story of Integer Holdings</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Integer Holdings showcased positive performance, achieving a revenue growth rate of 7.26% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Integer Holdings's net margin is impressive, surpassing industry averages. With a net margin of -5.14%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Integer Holdings's ROE excels beyond industry benchmarks, reaching -1.39%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Integer Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.71%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.84, Integer Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITGR

Analyst Expectations For Integer Holdings's Future

6 analysts have shared their evaluations of Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $218.5, along with a high estimate of $261.00 and a low estimate of $185.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.86%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747915222_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Becton Dickinson's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$196.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$224.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$261.00</td>
<td>$279.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Becton Dickinson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Becton Dickinson's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Becton Dickinson's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Becton Dickinson analyst ratings.</a>
<h2>Get to Know Becton Dickinson Better</h2>
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
<h3>Financial Milestones: Becton Dickinson's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Becton Dickinson displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.5%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Becton Dickinson's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.84%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.56%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.76.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Have This To Say About Becton Dickinson

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has positioned former Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) engineering chief Jay Parikh to spearhead its CoreAI division, implementing operational changes and cultural shifts as the tech giant advances its &#8220;age of AI agents&#8221; strategy under CEO Satya Nadella.
What Happened: CEO Satya Nadella appointed Jay Parikh as Executive Vice President of CoreAI Platform and Tools in January, consolidating nearly 10,000 employees under his leadership, <a href="https://www.businessinsider.com/memos-how-satya-nadellas-ai-czar-plans-to-change-microsoft-2025-5">reported</a> Business Insider. Parikh, who served as Meta&#8217;s global head of engineering for 11 years, now oversees teams from the developer division, AI platform, and Office of the CTO.
Internal memos reveal Parikh&#8217;s &#8220;agent factory&#8221; vision has generated measurable results. Microsoft&#8217;s AI platform Foundry delivered $337 million in favorable cost of goods sold impact year-to-date, with projected annualized savings of $606 million. The division secured new enterprise clients, including 5,000-plus GitHub Copilot Business seats for Fidelity, potentially worth $2.28 million annually at $19 per user monthly pricing.
Parikh has initiated systematic operational reviews addressing what he termed Microsoft&#8217;s tendency to &#8220;treat symptoms rather than systems.&#8221; His reforms include mandatory post-launch debriefs, &#8220;Ops Review&#8221; assessments across teams, and &#8220;get well plans&#8221; for dissatisfied customers following service incidents.
See Also: <a href="https://www.benzinga.com/general/biotech/25/05/45561443/sanofi-boosts-alzheimers-pipeline-with-vigil-neuroscience-acquisition">Sanofi Boosts Alzheimer&#8217;s Pipeline With Vigil Neuroscience Acquisition</a>
Why It Matters: Microsoft&#8217;s CoreAI reorganization reflects broader industry adoption of AI-powered development tools, with Nadella recently disclosing that artificial intelligence <a href="https://www.benzinga.com/tech/25/04/45093643/ai-is-reshaping-coding-at-microsoft-says-nadella-30-of-code-now-ai-generated">now writes 20-30% of Microsoft&#8217;s</a> codebase. 
The appointment follows Microsoft&#8217;s $80 billion <a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence">commitment to AI-driven</a> data centers and positions the company to compete against rivals in enterprise AI automation.
Parikh&#8217;s operational focus addresses scalability challenges as Microsoft&#8217;s AI business surpassed $13 billion in annual revenue, growing 175% year-over-year. His experience scaling Meta&#8217;s infrastructure during 11 years of platform expansion provides relevant expertise as Microsoft navigates increased demand for Azure cloud services and Copilot deployments.
The cultural transformation initiative aligns with <a href="https://in.benzinga.com/news/24/12/42679515/microsoft-invested-nearly-14-billion-in-openai-but-now-its-reducing-its-dependence-on-the-chatgpt-pa">Microsoft&#8217;s strategy to reduce OpenAI dependence</a> while expanding internal AI capabilities. Bank of America Securities and Goldman Sachs maintain positive outlooks on Microsoft&#8217;s positioning across cloud infrastructure and productivity software, citing sustainable growth prospects in AI-driven enterprise solutions.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45561399/jamie-dimon-says-us-is-not-in-a-sweet-spot-flags-stagflation-risk-and-deficit-problems-amid-trump-china-tensions">Jamie Dimon Says US Is Not In A &#8216;Sweet Spot,&#8217; Flags Stagflation Risk And Deficit Problems Amid Trump-China Tensions</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Bumble Dee on Shutterstock

General

MSFT

Microsoft Taps Former Meta Exec Jay Parikh To Lead CoreAI, Drive $600M In Projected Savings With 'Agent Factory' Vision

William Blair analyst Sebastien Naji initiates coverage on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Outperform rating.

Initiation

ALAB

William Blair Initiates Coverage On Astera Labs with Outperform Rating

Citigroup analyst Joanna Wiensch downgrades Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Buy to Neutral and lowers the price target from $217 to $185.

Downgrades

Price Target

Citigroup Downgrades Becton Dickinson to Neutral, Lowers Price Target to $185

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgraded the rating for UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) from Buy to Neutral. UroGen Pharma shares closed at $4.17 on Wednesday. <a href="https://www.benzinga.com/quote/URGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Heckmann downgraded Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) from Buy to Neutral and announced a $226 price target. Guidewire Software shares closed at $210.84 on Wednesday. <a href="https://www.benzinga.com/quote/GWRE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Lydia Rainforth downgraded the rating for Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Overweight to Equal-Weight. Equinor shares closed at $23.62 on Wednesday. <a href="https://www.benzinga.com/quote/EQNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Laura Chico downgraded Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) from Outperform to Neutral and lowered the price target from $13 to $8. Vigil Neuroscience shares closed at $2.31 on Wednesday. <a href="https://www.benzinga.com/quote/VIGL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Patrick Donnelly downgraded Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Neutral and cut the price target from $50 to $40. Bruker shares closed at $36.45 on Wednesday. <a href="https://www.benzinga.com/quote/brkr/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GWRE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="607" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-1024x607.png" alt="" class="wp-image-924250" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-1024x607.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-768x455.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

BRKR

EQNR

URGN

VIGL

This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Citigroup analyst Joanne Wuensch upgrades Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) from Neutral to Buy and raises the price target from $133 to $140.

Upgrades

Citigroup Upgrades Integer Holdings to Buy, Raises Price Target to $140

Mortgage demand slipped again last week as average 30-year loan costs jumped to 6.92%, the steepest level since February.
What Happened: Mortgage applications fell for a second straight week as borrowing costs climbed to a three-month high, the Mortgage Bankers Association said Wednesday. The group's Market Composite Index, a measure of total loan volume, dropped 5.1% on a seasonally adjusted basis for the week that ended on May 16.
The average contract rate for a 30-year fixed mortgage with balances up to $806,500 rose six basis points to 6.92%, the loftiest reading since mid-February and just shy of year-ago levels. Points edged up to 0.69 from 0.68 for loans requiring 20% down.
"Mortgage rates jumped to their highest level since February last week, with investors concerned about <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45484549/inflation-still-tops-americans-financial-concerns-but-worries-are-shifting">rising inflation</a> and the impact of <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45220645/us-trade-deficit-soars-to-record-140b-as-imports-rocket-ahead-of-trumps-tariffs">increasing deficits</a> and debt," said Mike Fratantoni, MBA's SVP and Chief Economist.
See also: <a href="https://www.benzinga.com/news/25/05/45560682/trumps-doge-initiative-moves-into-ntsb-amid-firings-and-safety-oversight-concerns">Trump&#8217;s DOGE Assigns Review Team To Examine NTSB Amid Firings And Safety Oversight Concerns</a>
Refinance requests also declined 5% and were 27% above year-earlier levels, with few homeowners able to lock in meaningful savings now that mortgage rates hover near those of 2023.
Why It Matters: Spring normally brings a burst of sales, yet fresh listings are outrunning demand. Realtor.com data show new listings up 11.2% year-over-year, giving shoppers more choice even as monthly payments swell. Redfin reports national inventory has climbed to a five-year high, but high costs keep many buyers on the fence.
The surge in mortgage costs also tracks a broader bond-market sell-off spurred by Moody's recent <a href="https://www.benzinga.com/25/05/45492889/americas-credit-strength-just-got-cut-again-should-you-panic">U.S. credit downgrade</a> and Congress' debate over a multitrillion-dollar tax-and-spending plan. Freddie Mac data show loans had stayed under 7% for 17 consecutive weeks before the latest breakout.
Read next: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45560658/if-you-invested-1000-in-bitcoin-when-dave-ramsey-called-fans-of-the-crypto-stupid-heres-how-much-youd-have-today">If You Invested $1,000 In Bitcoin When Dave Ramsey Called Fans Of The Crypto &#8216;Stupid,&#8217; Here&#8217;s How Much You&#8217;d Have Today</a>
Image via Shutterstock

Financial Advisors

Personal Finance

Mortgage Rates Climb, Buyer Demand Falls — Even As Housing Inventory Hits Multi-Year High

Citigroup analyst Patrick Donnelly downgrades Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Neutral and lowers the price target from $50 to $40.

Citigroup Downgrades Bruker to Neutral, Lowers Price Target to $40

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) on Wednesday announced the&nbsp;Llama Startup Program, <a target="_blank" href="https://www.benzinga.com/topic/meta-platforms" rel="noreferrer noopener">which will empower</a> early-stage startups to innovate and build generative AI applications with&nbsp;Llama.
The Llama Startup Program is ideal for those building generative AI applications in various industries, including technology and software, financial services, healthcare and life sciences, telecommunications, and <a target="_blank" href="https://ai.meta.com/blog/llama-startup-program/" rel="noreferrer noopener">retail and eCommerce</a>.
The program invited incorporated startups that have raised less than $10 million in funding and have at least one developer on staff to apply.
Also Read: <a href="https://www.benzinga.com/25/01/43351386/metas-ai-investments-llama-expansion-and-ad-tech-drive-growth-earn-analyst-conviction" target="_blank" rel="noreferrer noopener">Meta&#8217;s AI Investments, Llama Expansion, Ad Tech Growth Earn Analyst Conviction</a>
Members of the Llama Startup Program will receive resources and support from Llama experts along their journey.
During the initial phase of the Llama Startup Program, Meta will reimburse the cost of using Llama through hosted APIs via cloud inference providers. Members may receive up to $6,000 per month for up to six months to help them offset the costs of building and enhancing their generative AI solutions.
This funding enables startups to experiment, innovate, and scale their solutions without the immediate financial burden. Members of the program will receive hands-on technical support from the Llama team.
In April, Meta announced that it had launched a <a href="https://www.benzinga.com/markets/25/05/45160454/mark-zuckerbergs-meta-targets-1-4-trillion-revenue-from-generative-ai-by-2035-court-filing-reveals" target="_blank" rel="noreferrer noopener">standalone AI app</a>, built with Llama 4, to compete with OpenAI&#8216;s ChatGPT, Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&#8217;s Gemini, and xAI&#8216;s Grok by providing users with a more personalized AI experience. The company projected that its generative AI products could potentially rake in revenue of $460 billion-$1.4 trillion by the year 2035.
Price Action:&nbsp;META stock is up 0.39% at $638.00 premarket at the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45548478/alibabas-home-province-launches-138-billion-ai-push-to-double-chinas-industry-output-by-2027" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s Home Province Launches $138 Billion AI Push To Double China&#8217;s Industry Output By 2027</a></li>
</ul>
Image via Shutterstock

Tech

GOOG

GOOGL

Meta Offers AI Startups Free Tools, Funding To Boost Llama Model Adoption

Citigroup analyst Scott Gruber initiates coverage on Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) with a Buy rating and announces Price Target of $32.

Citigroup Initiates Coverage On Solaris Energy with Buy Rating, Announces Price Target of $32

Wedbush analyst Laura Chico downgrades Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) from Outperform to Neutral and lowers the price target from $13 to $8.

Wedbush Downgrades Vigil Neuroscience to Neutral, Lowers Price Target to $8

The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">FLEX LNG Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>)</h3>
<ul class="wp-block-list">
<li>On May 21, Flex LNG posted better-than-expected quarterly earnings. Marius Foss, Interim CEO of Flex LNG Management AS, said, &#8220;Flex LNG delivered solid results for the first quarter, with revenues of $88.4 million, or $86.8 million excluding EUAs. Net income came in at $18.7 million, translating to earnings per share (EPS) of $0.35 and adjusted net income came in at $29.4 million, or $0.54 per share. As expected, revenue decreased by $3 million compared to Q4 2024 primarily due to lower earnings from Flex Artemis, operating on a variable index hire.&#8221; The company's stock fell around 9% over the past five days and has a 52-week low of $19.46.</li>
<li>RSI Value: 27.9</li>
<li>FLNG Price Action: Shares of FLEX LNG fell 8.2% to close at $22.39 on Wednesday.</li>
<li>Edge Stock Ratings: 24.66 Momentum score with Value at 71.53. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/FLNG"><img loading="lazy" decoding="async" width="486" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22044048/image-277.png" alt="" class="wp-image-924003" style="width:316px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22044048/image-277.png 486w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22044048/image-277-300x113.png 300w" sizes="(max-width: 486px) 100vw, 486px" /></a></figure>
<h3 class="wp-block-heading">Helmerich and Payne Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 19, Citigroup analyst Scott Gruber downgraded Helmerich &amp; Payne from Buy to Neutral and lowered the price target from $25 to $19. The company's stock fell around 23% over the past month and <a href="https://www.benzinga.com/quote/HP">has a 52-week low</a> of $15.21.</li>
<li>RSI Value: 23.1</li>
<li>HP Price Action: Shares of Helmerich and Payne fell 5.6% to close at $15.21 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522">HP stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522"><img loading="lazy" decoding="async" width="927" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22044147/image-278.png" alt="" class="wp-image-924007" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22044147/image-278.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22044147/image-278-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22044147/image-278-768x698.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">Ring Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REI#NYSE">REI</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Ring Energy posted weaker-than-expected quarterly earnings. Mr. Paul D. McKinney, Chairman of the Board and Chief Executive Officer, commented, &#8220;We&#8217;re excited to kick off 2025 with a strong first quarter, showcasing the flexibility, resilience, and strength of our proven, value-focused strategy amid fluctuating oil prices. Our performance met or surpassed all guidance targets, driven by exceptional oil sales volumes.&#8221; The company's stock fell around 15% over the past five days and has a 52-week<a href="https://www.benzinga.com/quote/REI"> low of $0.74</a>.</li>
<li>RSI Value: 29.9</li>
<li>REI Price Action: Shares of Ring Energy fell 4.2% to close at $0.75 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522"> REI shares</a>.</li>
</ul>
How do other stocks rank? Get the full <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">BZ Edge Rankings breakdown here</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

FLNG

Top 3 Energy Stocks That Could Lead To Your Biggest Gains This Quarter

Crypto markets are surging on early Thursday, with Bitcoin hitting a new all-time high above $110,000 amid accelerating institutional adoption and robust ETF inflows.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$110,681.06</td>
<td>+4%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,650.22</td>
<td>+4.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$178.1</td>
<td>+5.3%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.41</td>
<td>+2.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2395</td>
<td>+5.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001523</td>
<td>+4.9%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction increased by 22.1% and 36.9%, respectively, while BTC's daily active addresses went up by 7.7% and exchange netflows are up by 332.7%.</li>
<li>Coinglass data shows 125,650 traders were liquidated in the past 24 hours for $505.49 million.</li>
<li>SoSoValue data shows $608.99 million in net inflows into spot Bitcoin ETFs and $587,000 in net inflows into spot Ethereum ETFs.</li>
<li>CoinGlass data <a href="https://x.com/coinglass_com/status/1925449040130711574">shows</a> selling pressure for Bitcoin with nearly $200 million in stacked sell orders between $111,000–$113,200, with ~$8 million per $100 increment totalling around $200 million in cumulative sell pressure.</li>
<li><a href="https://x.com/coinbureau/status/1925463469714817335">According</a> to Coin Bureau, retail investors have yet to fully enter the market as wallets holding less than 1 BTC (&#8220;shrimp&#8221; addresses) remain lower than in May 2024 and January 2021. Once retail floods in, sentiment could turn euphoric.</li>
</ul>
Trader Notes: Glassnode data <a href="https://x.com/glassnode/status/1925484339002745285">reports</a> only $1 billion in profit-taking at Bitcoin's new all-time high, less than half the $2.1 billion seen when Bitcoin first crossed $100,000 in December. This suggests investors are holding tight for more upside.
Crypto trader Jelle sees Bitcoin having a target of $180,000 while Trader Tardigrade says Bitcoin broke out of a key battleground between bulls and bears and the bulls are now fully in charge and have emerged victorious.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> was caught in a tug-of-war between Bulls and Bears along the Bull/Bear Battle Line. Ultimately, the Bulls emerged victorious &#x1f525; Bulls now have full control of <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> &#x1f680; <a href="https://t.co/g7mF1CntMT">pic.twitter.com/g7mF1CntMT</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1925495872613490726?ref_src=twsrc%5Etfw">May 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Dogecoin is breaking out of a bull pennant, with Ali Martinez targeting $0.31.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> appears to be breaking out of a bull pennant, which suggests a target of $0.31! <a href="https://t.co/Hbzuwd7Akk">pic.twitter.com/Hbzuwd7Akk</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1925349892714615046?ref_src=twsrc%5Etfw">May 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Jelle <a href="https://x.com/CryptoJelleNL/status/1925477625474044354">remains </a>confident in his Solana holdings, expecting a strong rally once it clears $250. He expects a surge to $400–$500 once it clears resistance, as &#8220;weak hands&#8221; have already been flushed out.
Ethereum is holding strong, but Jelle <a href="https://x.com/CryptoJelleNL/status/1925482983965802725">believes</a> the real rally begins once it reclaims $3,000, which could trigger a broader market wave.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45541858/germany-sold-50000-bitcoin-below-60000-heres-how-much-it-missed-out-on">Germany Sold 50,000 Bitcoin Below $60,000: Here&#8217;s How Much It Missed Out On</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin Shatters $110,000, XRP, Dogecoin, Ethereum Surge: 'Bulls Emerge Victorious,' Trader Concludes

OSR Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>), a public company dedicated to advancing innovation in healthcare and wellness, announced today that it has entered into a Memorandum of Understanding (MOU) with BCM Europe AG, its major shareholder, and Taekwondo Cooperative (TKD Coop), a global Taekwondo community organization, to explore the joint development of a security token, provisionally named the "OSRH Token". The initiative aims to enhance access to crypto-based liquidity and&nbsp;provide a basis for OSRH to launch crypto treasury strategies.

OSRH

OSR Holdings Enters Into MOU With BCM Europe And Taekwondo To Explore Joint Development Of Security Token, Provisionally Named "OSRH Token"

Press Releases

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Health Care

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Comments

Olema Pharmaceuticals

Notizie

Ultime notizie per Olema Pharmaceuticals (NASDAQ:OLMA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO